A novel self-controlled electroacupuncture helmet for chemotherapy-induced cognitive impairment: Results from a prospective randomized trial.

337 Background: Chemotherapy-induced cognitive impairment (CICI) affects 30% of cancer patients, with limited treatment options. Traditional acupuncture suffers from efficacy variability (±40%), while transcranial magnetic stimulation (TMS) devices are costly ($75,000/unit) and confined to hospitals. We developed a self-controlled electroacupuncture helmet (SCEH) with multi-point stimulation and neural adaptive technology to address these limitations. Methods: In this single-blind, randomized trial (NCT05876988), 83 CICI patients (MoCA≤26) were allocated to SCEH (6-channel NAU stimulation) vs. sham device (1-channel). Treatment consisted of 45-minute sessions twice weekly for 8 weeks. Primary endpoint was MoCA score change at week 4. Secondary endpoints included digit span test, EORTC QLQ-C30, and safety. Results: The SCEH group showed significantly greater MoCA improvement at week 4 (Δ4.2±0.8 vs. 1.3±0.6, p